CA3293530A1 - Farnesyltransferase inhibitors for treatment of kras-dependent cancers - Google Patents

Farnesyltransferase inhibitors for treatment of kras-dependent cancers

Info

Publication number
CA3293530A1
CA3293530A1 CA3293530A CA3293530A CA3293530A1 CA 3293530 A1 CA3293530 A1 CA 3293530A1 CA 3293530 A CA3293530 A CA 3293530A CA 3293530 A CA3293530 A CA 3293530A CA 3293530 A1 CA3293530 A1 CA 3293530A1
Authority
CA
Canada
Prior art keywords
kras
treatment
dependent cancers
farnesyltransferase inhibitors
farnesyltransferase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3293530A
Other languages
French (fr)
Inventor
Francis Burrows
Shivani Malik
Alison Smith
Hetika VORA PATEL
Original Assignee
Kura Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kura Oncology Inc filed Critical Kura Oncology Inc
Publication of CA3293530A1 publication Critical patent/CA3293530A1/en
Pending legal-status Critical Current

Links

CA3293530A 2023-05-31 2024-05-30 Farnesyltransferase inhibitors for treatment of kras-dependent cancers Pending CA3293530A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63/505,272 2023-05-31
US63/580,680 2023-09-05
US63/556,282 2024-02-21
US63/639,307 2024-04-26

Publications (1)

Publication Number Publication Date
CA3293530A1 true CA3293530A1 (en) 2024-12-05

Family

ID=

Similar Documents

Publication Publication Date Title
CA3261042A1 (en) Macrocyclic inhibitors of kras for the treatment of cancer
IL316829A (en) Menin-mll inhibitors for the treatment of cancer
EP4111202A4 (en) Methods of treating cancer
IL312650A (en) Cdk4 inhibitor for the treatment of cancer
EP4100065A4 (en) Use of mirna-485 inhibitors for treating tauopathy
IL314687A (en) Treatment of cancer
AU2021372815A9 (en) Combination treatment of cancer
HK40120366A (en) Treatment of cancer
CA3303484A1 (en) Bet inhibitors for the treatment of cancer
HK40105324A (en) Methods for treatment of cancers
HK40090883A (en) Treatment of cancer
CA3302582A1 (en) Molecules for treatment of cancer
HK40093325A (en) Use of ezh2 inhibitors for treating cancer
CA3310617A1 (en) Methods of treating cancer
AU2024377510A1 (en) Methods of treating cancer
CA3293232A1 (en) Methods of treating cancer
HK40090718A (en) Atr inhibitors for the treatment of cancer
HK40121406A (en) Treatment of solid tumors
CA3273527A1 (en) Metap2 inhibitors for the treatment of prostate cancer
EP4313077A4 (en) Combination for treatment of thromboinflammation
CA3264674A1 (en) Treatment of fasciolosis
AU2024298849A1 (en) Psma-targeted radiopharmaceuticals for treatment of cancer
CA3296090A1 (en) Psma-targeted radiopharmaceuticals for treatment of cancer
CA3273444A1 (en) Inhibitors of rock2
HK40122640A (en) Inhibitors of rock2